267 related articles for article (PubMed ID: 34466224)
1. Patients with marginal zone dural lymphoma successfully treated with rituximab and bendamustine: A report of two cases.
Tsutsumi Y; Ito S; Nagai J; Tateno T; Teshima T
Mol Clin Oncol; 2021 Oct; 15(4):208. PubMed ID: 34466224
[TBL] [Abstract][Full Text] [Related]
2. Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
Kiesewetter B; Mayerhoefer ME; Lukas J; Zielinski CC; Müllauer L; Raderer M
Ann Hematol; 2014 Feb; 93(2):249-53. PubMed ID: 23925930
[TBL] [Abstract][Full Text] [Related]
3. Results of Upfront Therapy for Marginal Zone Lymphoma.
Ortega JL; Cabanillas F; Rivera N; Tirado-Gomez M; Hallman D; Pardo WI; Bruno M
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):879-883. PubMed ID: 29042174
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
[TBL] [Abstract][Full Text] [Related]
5. A case of conjunctival MALT lymphoma: successfully treated with solely extended rituximab therapy.
Celiker H; Toker E; Kaygusuz Atagunduz I
Int Ophthalmol; 2019 Mar; 39(3):687-691. PubMed ID: 29411260
[TBL] [Abstract][Full Text] [Related]
6. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial.
Salar A; Domingo-Domenech E; Panizo C; Nicolás C; Bargay J; Muntañola A; Canales M; Bello JL; Sancho JM; Tomás JF; Rodríguez MJ; Peñalver FJ; Grande C; Sánchez-Blanco JJ; Palomera L; Arranz R; Conde E; García M; García JF; Caballero D; Montalbán C;
Lancet Haematol; 2014 Dec; 1(3):e104-11. PubMed ID: 27029228
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma.
Raderer M; Jäger G; Brugger S; Püspök A; Fiebiger W; Drach J; Wotherspoon A; Chott A
Oncology; 2003; 65(4):306-10. PubMed ID: 14707449
[TBL] [Abstract][Full Text] [Related]
8. Chemoimmunotherapy for Mucosa-Associated Lymphoid Tissue-Type Lymphoma: A Review of the Literature.
Kiesewetter B; Ferreri AJ; Raderer M
Oncologist; 2015 Aug; 20(8):915-25. PubMed ID: 26156327
[TBL] [Abstract][Full Text] [Related]
9. Dural MALT lymphoma with disseminated disease.
Matmati K; Matmati N; Hannun YA; Rumboldt Z; Patel S; Lazarchick J; Stuart R; Giglio P
Hematol Rep; 2010 Jan; 2(1):e10. PubMed ID: 22184513
[TBL] [Abstract][Full Text] [Related]
10. Marginal zone lymphoma (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue: a study of 15 patients.
Bailey EM; Ferry JA; Harris NL; Mihm MC; Jacobson JO; Duncan LM
Am J Surg Pathol; 1996 Aug; 20(8):1011-23. PubMed ID: 8712288
[TBL] [Abstract][Full Text] [Related]
11. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients.
Zhang T; Wu Y; Ju H; Meng J; Guo W; Ren G
Cancer Med; 2020 Jan; 9(1):194-203. PubMed ID: 31733094
[TBL] [Abstract][Full Text] [Related]
12. The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.
Laribi K; Tempescul A; Ghnaya H; Denizon N; Besançon A; Anghel A; Farhi J; Truong C; Lemaire P; Poulain S; Bolle D; Ianotto JC; Baugier de Materre A
Hematol Oncol; 2017 Dec; 35(4):536-541. PubMed ID: 27443419
[TBL] [Abstract][Full Text] [Related]
13. Primary central nervous system mucosa-associated lymphoid tissue lymphoma: case report and literature review.
Razaq W; Goel A; Amin A; Grossbard ML
Clin Lymphoma Myeloma; 2009 Jun; 9(3):E5-9. PubMed ID: 19525185
[TBL] [Abstract][Full Text] [Related]
14. Minimal change disease: an unusual presentation of marginal zone MALT lymphoma.
Inayat F; Law JK; Myers-Gurevitch PM; Seshan SV; Perlman AS
Clin Nephrol; 2016 Mar; 85(3):184-8. PubMed ID: 26636329
[TBL] [Abstract][Full Text] [Related]
15. Intracranial mucosa-associated lymphoid tissue (MALT) lymphoma.
Ferguson SD; Musleh W; Gurbuxani S; Shafizadeh SF; Lesniak MS
J Clin Neurosci; 2010 May; 17(5):666-9. PubMed ID: 20202849
[TBL] [Abstract][Full Text] [Related]
16. Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma of the Colon: A Case Report and a Literature Review.
Abbas H; Niazi M; Makker J
Am J Case Rep; 2017 May; 18():491-497. PubMed ID: 28469125
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
[TBL] [Abstract][Full Text] [Related]
18. Rituximab-Bendamustine (R-Benda) in MALT lymphoma complicating primary Sjögren syndrome (pSS).
Demaria L; Henry J; Seror R; Frenzel L; Hermine O; Mariette X; Nocturne G
Br J Haematol; 2019 Feb; 184(3):472-475. PubMed ID: 29424433
[No Abstract] [Full Text] [Related]
19. Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma.
Pinnix CC; Gunther JR; Milgrom SA; Cruz Chamorro RJ; Medeiros LJ; Khoury JD; Amini B; Neelapu S; Lee HJ; Westin J; Fowler N; Nastoupil L; Dabaja B
Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):447-455. PubMed ID: 30769175
[TBL] [Abstract][Full Text] [Related]
20. Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone.
Aguiar-Bujanda D; Llorca-Mártinez I; Rivero-Vera JC; Blanco-Sánchez MJ; Jiménez-Gallego P; Mori-De Santiago M; Limeres-Gonzalez MA; Cabrera-Marrero JC; Hernández-Sosa M; Galván-Ruíz S; Hernández-Sarmiento S; Saura Grau S; Bohn-Sarmiento U
Hematol Oncol; 2014 Sep; 32(3):139-44. PubMed ID: 24123108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
